Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
109.6 USD | -3.09% | -0.35% | -10.87% |
Sales 2024 * | 4.05B 5.54B | Sales 2025 * | 4.36B 5.96B | Capitalization | 6.91B 9.45B |
---|---|---|---|---|---|
Net income 2024 * | 430M 588M | Net income 2025 * | 619M 846M | EV / Sales 2024 * | 2.58 x |
Net Debt 2024 * | 3.55B 4.85B | Net Debt 2025 * | 2.05B 2.81B | EV / Sales 2025 * | 2.06 x |
P/E ratio 2024 * |
18.6
x | P/E ratio 2025 * |
12
x | Employees | 2,800 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.22% |
Latest transcript on Jazz Pharmaceuticals plc
1 day | -3.09% | ||
1 week | -0.35% | ||
Current month | -1.01% | ||
1 month | -0.86% | ||
3 months | -11.76% | ||
6 months | -8.79% | ||
Current year | -10.87% |
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Renée Galá
PSD | President | 52 | 20-03-15 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 19-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-12 |
Patrick Enright
BRD | Director/Board Member | 62 | 08-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.34% | 13 M€ | -.--% | ||
14.47% | 254 M€ | +12.39% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 109.6 | -3.09% | 564,155 |
24-05-09 | 113.1 | +2.19% | 812,109 |
24-05-08 | 110.7 | -0.46% | 771,168 |
24-05-07 | 111.2 | +1.24% | 841,956 |
24-05-06 | 109.8 | -0.15% | 571,216 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.87% | 6.91B | |
+30.38% | 684B | |
+29.55% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.02% | 240B | |
+9.27% | 208B | |
-7.28% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- JAZZ Stock